These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10706648)

  • 1. Management of advanced prostate cancer.
    Auclerc G; Antoine EC; Cajfinger F; Brunet-Pommeyrol A; Agazia C; Khayat D
    Oncologist; 2000; 5(1):36-44. PubMed ID: 10706648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [General treatment of metastatic prostatic cancer].
    Auclerc G
    Ann Urol (Paris); 2000 Feb; 34(1):39-48. PubMed ID: 10763423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
    Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
    Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
    Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
    Brundage MD; Crook JM; Lukka H
    Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The role of systemic radiotherapy in the combined treatment for hormone-resistant prostate cancer].
    Solodky VA; Pavlov AY; Panshin GA; Gafanov RA; Fastovets SV; Isaev TK
    Vopr Onkol; 2015; 61(1):31-3. PubMed ID: 26016142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review.
    Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
    BJU Int; 2015 Jul; 116(1):30-6. PubMed ID: 25523493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New development of endocrine therapy in prostate cancer].
    Naito S
    Gan To Kagaku Ryoho; 1996 May; 23(6):684-8. PubMed ID: 8645018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combined treatment for pain from bone metastases in patients with prostate cancer].
    Ren X; Ying J; Yao D; Ye C; Jiang Y
    Zhonghua Nan Ke Xue; 2004 Mar; 10(3):188-90. PubMed ID: 15080063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances and trends in hormonal therapy for advanced prostate cancer.
    Debruyne FM; Dijkman GA
    Eur Urol; 1995; 28(3):177-88. PubMed ID: 8536770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F; Dupont A; Belanger A
    Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
    [No Abstract]   [Full Text] [Related]  

  • 15. Systemic radionuclide therapy of bone metastases with strontium-89.
    Porter AT; Davis LP
    Oncology (Williston Park); 1994 Feb; 8(2):93-6; discussion 96, 99-101. PubMed ID: 8167090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
    Prescrire Int; 2013 Feb; 22(135):48-51. PubMed ID: 23444510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care?
    Mason M
    J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S27-35. PubMed ID: 16896883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiandrogens in the treatment of prostate cancer.
    Wirth MP; Hakenberg OW; Froehner M
    Eur Urol; 2007 Feb; 51(2):306-13; discussion 314. PubMed ID: 17007995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.